Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
SAVA Quote, Financials, Valuation and Earnings
Last price:
$2.23
Seasonality move
:
23.43%
Day range:
$2.17 - $2.24
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.32x
Volume:
416.4K
Avg. volume:
1.2M
1-year change:
-4.7%
Market cap:
$107.7M
Revenue:
--
EPS (TTM):
-$2.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.34 | 11.37% | 43.52% | $89.74 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.60 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
YCBD
cbdMD, Inc.
|
$4.7M | -- | 3.2% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
$2.23 | $8.00 | $107.7M | -- | $0.00 | 0% | 2.69x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$60.16 | $89.74 | $11.6B | 22.54x | $0.00 | 0% | 3.81x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
GERN
Geron Corp.
|
$1.40 | $3.60 | $893.7M | -- | $0.00 | 0% | 5.08x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
YCBD
cbdMD, Inc.
|
$1.59 | $2.00 | $14.2M | -- | $0.00 | 0% | 0.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.880 | -- | 2.21x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
YCBD
cbdMD, Inc.
|
9.72% | 3.470 | 7.22% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
YCBD
cbdMD, Inc.
|
$2.5M | -$685.8K | -43.37% | -57.5% | -14.53% | -$243.5K |
Cassava Sciences, Inc. vs. Competitors
-
Which has Higher Returns SAVA or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -3.91%. Cassava Sciences, Inc.'s return on equity of -86.98% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About SAVA or BMRN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 258.74%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.74 which suggests that it could grow by 46.78%. Given that Cassava Sciences, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Cassava Sciences, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 BMRNBioMarin Pharmaceutical, Inc.13 7 0 -
Is SAVA or BMRN More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.071%.
-
Which is a Better Dividend Stock SAVA or BMRN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or BMRN?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Cassava Sciences, Inc.'s net income of -$10.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 3.81x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M BMRNBioMarin Pharmaceutical, Inc.3.81x 22.54x $786.8M -$30.7M
-
Which has Higher Returns SAVA or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of 10.24%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About SAVA or FOLD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 258.74%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that Cassava Sciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is SAVA or FOLD More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock SAVA or FOLD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or FOLD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns SAVA or GERN?
Geron Corp. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -39.02%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About SAVA or GERN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 258.74%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 157.14%. Given that Cassava Sciences, Inc. has higher upside potential than Geron Corp., analysts believe Cassava Sciences, Inc. is more attractive than Geron Corp..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 GERNGeron Corp.3 1 1 -
Is SAVA or GERN More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock SAVA or GERN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or GERN?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Cassava Sciences, Inc.'s net income of -$10.8M is higher than Geron Corp.'s net income of -$18.4M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 5.08x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M GERNGeron Corp.5.08x -- $47.2M -$18.4M
-
Which has Higher Returns SAVA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -255.85%. Cassava Sciences, Inc.'s return on equity of -86.98% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SAVA or NBY?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 258.74%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SAVA or NBY More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SAVA or NBY?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or NBY?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cassava Sciences, Inc.'s net income of -$10.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns SAVA or YCBD?
cbdMD, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -14.4%. Cassava Sciences, Inc.'s return on equity of -86.98% beat cbdMD, Inc.'s return on equity of -57.5%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M YCBDcbdMD, Inc.53.28% -$0.08 $8M -
What do Analysts Say About SAVA or YCBD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 258.74%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 25.79%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 YCBDcbdMD, Inc.0 0 0 -
Is SAVA or YCBD More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.218, suggesting its more volatile than the S&P 500 by 121.825%.
-
Which is a Better Dividend Stock SAVA or YCBD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or YCBD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than cbdMD, Inc. quarterly revenues of $4.7M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than cbdMD, Inc.'s net income of -$680K. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 0.41x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M YCBDcbdMD, Inc.0.41x -- $4.7M -$680K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
